NCT06102707
The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients treatment Not Available not_yet_recruiting NCT01332656
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel treatment 2 completed NCT05095558
Microtransplantation for Ovarian Cancer No drug interventions treatment 1 / 2 recruiting NCT03983226
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) treatment 2 recruiting NCT05001282
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) No drug interventions treatment 1 / 2 terminated NCT03162562
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer treatment 1 terminated NCT05990192
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy treatment 2 recruiting NCT03717610
Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer No drug interventions other Not Available unknown_status NCT01111903
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse treatment 1 / 2 completed NCT04149145
Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer treatment 1 withdrawn NCT06014528
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer treatment 2 recruiting NCT03827837
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors treatment 2 unknown_status NCT04175470
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer treatment 2 active_not_recruiting NCT04072263
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer treatment 1 / 2 unknown_status NCT01485848
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer treatment 2 completed NCT03681548
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. treatment 1 completed NCT03657966
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer treatment 2 completed NCT03734692
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer treatment 1 / 2 recruiting NCT01874353
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy treatment 3 active_not_recruiting NCT03534453
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy treatment 3 active_not_recruiting NCT05080556
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer treatment 2 recruiting NCT04517357
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients treatment 2 unknown_status NCT02825420
Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients Not Available Not Available completed NCT06081595
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment treatment 2 not_yet_recruiting NCT04713514
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC treatment 2 recruiting NCT05479487
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment treatment 2 not_yet_recruiting NCT04999605
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer treatment 1 / 2 terminated NCT04887961
Reprab Study: PLD + Trabectedin Rechallenge treatment 2 unknown_status NCT05607329
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial No drug interventions treatment Not Available recruiting NCT03458221
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER treatment 2 / 3 recruiting NCT05311579
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer treatment 2 unknown_status NCT01637532
Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer treatment 1 / 2 completed NCT01869400
An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer No drug interventions Not Available Not Available completed NCT05942300
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer treatment 1 recruiting NCT05126342
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi treatment 2 not_yet_recruiting NCT06308406
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer treatment 1 / 2 recruiting NCT02117817
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer treatment 1 withdrawn NCT05270720
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer No drug interventions treatment 1 unknown_status NCT02090582
H.O.P.E: Helping Ovarian Cancer Patients Cope No drug interventions supportive_care Not Available completed NCT02195973
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer treatment 1 completed NCT04457089
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer treatment 0 recruiting NCT06107868
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer treatment 1 active_not_recruiting NCT01851746
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer No drug interventions Not Available Not Available unknown_status NCT02303912
Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer treatment 1 completed NCT01809379
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer treatment 2 completed NCT02737787
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer treatment 1 completed NCT01659554
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers treatment 2 terminated NCT06365853
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression treatment 2 recruiting NCT02849353
Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer No drug interventions treatment 1 / 2 completed NCT02035345
Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment supportive_care 4 terminated NCT03632798
Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer No drug interventions diagnostic 3 suspended NCT01381861
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma treatment 2 completed NCT05335993
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. treatment 2 active_not_recruiting NCT01639885
Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer treatment 1 / 2 completed NCT06070285
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients No drug interventions Not Available Not Available not_yet_recruiting NCT03618706
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer No drug interventions treatment 2 unknown_status NCT01802749
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer treatment 3 active_not_recruiting NCT02083536
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma treatment 1 withdrawn NCT03430518
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer treatment 1 completed NCT06257758
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT05610735
Combination Therapy for Recurrent Ovarian Cancer treatment 1 / 2 recruiting NCT05819060
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab treatment 2 not_yet_recruiting NCT03564340
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers treatment 1 / 2 recruiting NCT04718740
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer basic_science 1 completed NCT03025867
Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer Not Available Not Available approved_for_marketing NCT06560112
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer treatment 2 not_yet_recruiting NCT03776812
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer treatment 2 unknown_status NCT01626014
Interactive Educational Website for Women With Ovarian Cancer & Caregivers No drug interventions supportive_care 0 completed NCT02788708
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer treatment 1 completed